...
首页> 外文期刊>Ukrainian Biochemical Journal >Hematologic features of beta-globin gene mutation type (βo) with homozygous beta thalassemia
【24h】

Hematologic features of beta-globin gene mutation type (βo) with homozygous beta thalassemia

机译:β-珠蛋白基因突变型(βo)与纯合性β地中海贫血的血液学特征

获取原文
           

摘要

β-Tthalassemia is common genetic disorders in Turkey that characterized by the reduced synthesis (βsup+/sup) or absence (βsupo/sup) of the β-globin chains in the HbA molecule. In this study, we aimed to determine the effect of the mutation type of the β-globin gene on hematological values in homozygous β-thalassemia. This retrospective study was undertaken by Prenatal Diagnosis Centres of Cukurova University Medical Biochemistry at Adana. We evaluated 60 homozygous by implementing DNA sequencing analysis for mutations undetectable by conventional methods. 30 patients with βo [FSC 44/ C-A] mutations and the other 30 patients with βsupo/sup [(IVS-II-1(GA), CD39 (CT), Cd8 (-AA) Cd39 C T and CD36/37 (–T)] mutations, totally 60 patients were included in the study. Erythrocyte indices, HbF, HbA2 levels were compared between the two groups. FSC 44/(-C) mutations were detected in patients. Hb, Hct, MCV in this group values were statistically lower than in patients with other detected mutations ( P 0.05). Between the two groups, there is no statistically different RBC, MCH, MCHC, HbF, HbA2 levels ( P ? 0.05). For the first time in this study, it was found that the Hb, Hct and MCV value of the persons who carried the FSC 44/(-C) mutation were significantly lower than the persons who carrying other mutations. Between the two groups, there was no statistical difference in RBC, MCH, MCHC, HbF and HbA2 levels. Awareness of FSC/44 mutation, which may have a heterogeneous clinical presentation, is required. We herein present the hematologic findings of a Turkish population carrying this mutation. This will also help to make a diagnosis.
机译:β-地中海贫血是土耳其常见的遗传性疾病,其特征是HbA分子中β-珠蛋白链的合成减少(β + )或不存在(β o )。在这项研究中,我们旨在确定β-珠蛋白基因突变类型对纯合性β地中海贫血患者血液学值的影响。这项回顾性研究由库纳库洛娃大学医学生物化学设在阿达纳的产前诊断中心进行。我们通过对常规方法无法检测到的突变进行DNA测序分析,评估了60个纯合子。 30例具有βo[FSC 44 / CA]突变的患者,其他30例具有β o [[(IVS-II-1(G> A),CD39(C> T),Cd8(-AA) )Cd39 C> T和CD36 / 37(–T)]突变,共纳入60例患者,比较了两组的红细胞指数,HbF,HbA2水平,并检测了FSC 44 /(-C)突变。在该组中,Hb,Hct,MCV值在统计学上低于具有其他检测到的突变的患者(P <0.05)。两组之间的RBC,MCH,MCHC,HbF,HbA2水平无统计学差异(P? 0.05)。这项研究首次发现,携带FSC 44 /(-C)突变的人的Hb,Hct和MCV值显着低于携带其他突变的人。两组之间,RBC,MCH,MCHC,HbF和HbA2水平无统计学差异,需要了解FSC / 44突变,可能具有不同的临床表现。携带这种突变的土耳其人的发现。这也将有助于做出诊断。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号